Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 6:40 pm Purchase | 2024-12-31 | 13G | Protara Therapeutics, Inc. TARA | RA CAPITAL MANAGEMENT L.P. | 3,431,713 9.900% | 1,358,638 (+65.54%) | Filing History |
| 2025-02-14 6:39 pm Sale | 2024-12-31 | 13G | MacroGenics, Inc. MGNX | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -4,053,077 (Position Closed) | Filing History |
| 2025-02-14 6:39 pm Sale | 2024-12-31 | 13G | Longboard Pharmaceuticals, Inc. LBPH | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -3,073,119 (Position Closed) | Filing History |
| 2025-02-14 6:38 pm Sale | 2024-12-31 | 13G | GlycoMimetics, Inc. GLYC | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -63,830 (Position Closed) | Filing History |
| 2025-02-14 6:37 pm Purchase | 2024-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | RA CAPITAL MANAGEMENT L.P. | 3,181,818 4.700% | 86,682 (+2.80%) | Filing History |
| 2025-02-14 6:36 pm Sale | 2024-12-31 | 13G | Evolent Health, Inc. EVH | RA CAPITAL MANAGEMENT L.P. | 3,577,197 3.100% | -4,701,906 (-56.79%) | Filing History |
| 2025-02-14 6:34 pm Sale | 2024-12-31 | 13G | Ensysce Biosciences, Inc. ENSC | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -98,400 (Position Closed) | Filing History |
| 2025-02-14 6:32 pm Sale | 2024-12-31 | 13G | Dianthus Therapeutics, Inc. DNTH | RA CAPITAL MANAGEMENT L.P. | 2,866,733 9.400% | -128,290 (-4.28%) | Filing History |
| 2025-02-14 6:31 pm Sale | 2024-12-31 | 13G | Day One Biopharmaceuticals, Inc. DAWN | RA CAPITAL MANAGEMENT L.P. | 5,755,577 5.700% | -2,054,275 (-26.30%) | Filing History |
| 2025-02-14 6:31 pm Purchase | 2024-12-31 | 13G | Adagio Medical Holdings, Inc. ADGM | RA CAPITAL MANAGEMENT L.P. | 1,613,220 9.900% | 275,407 (+20.59%) | Filing History |
| 2025-02-14 6:30 pm Sale | 2024-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | RA CAPITAL MANAGEMENT L.P. | 4,564,867 9.900% | -533,344 (-10.46%) | Filing History |
| 2025-02-14 6:29 pm Sale | 2024-12-31 | 13G | Cytek Biosciences, Inc. CTKB | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -6,809,404 (Position Closed) | Filing History |
| 2025-02-14 6:28 pm Sale | 2024-12-31 | 13G | Cybin Inc. CYBN | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -1,529,988 (Position Closed) | Filing History |
| 2025-02-14 6:28 pm Purchase | 2024-12-31 | 13G | CervoMed Inc. CRVO | RA CAPITAL MANAGEMENT L.P. | 916,063 9.900% | 90,690 (+10.99%) | Filing History |
| 2025-02-14 6:27 pm Sale | 2024-12-31 | 13G | BioAge Labs, Inc. BIOA | RA CAPITAL MANAGEMENT L.P. | 1,310,589 3.700% | -900,000 (-40.71%) | Filing History |
| 2025-02-14 6:27 pm Sale | 2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -1,999,997 (Position Closed) | Filing History |
| 2025-02-14 6:26 pm Sale | 2024-12-31 | 13G | Alto Neuroscience, Inc. ANRO | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -2,075,154 (Position Closed) | Filing History |
| 2025-02-14 6:25 pm Purchase | 2024-12-31 | 13G | Monopar Therapeutics Inc. MNPR | RA CAPITAL MANAGEMENT L.P. | 620,116 9.900% | 108,909 (+21.30%) | Filing History |
| 2025-02-14 6:24 pm Unchanged | 2024-12-31 | 13G | Zura Bio Limited ZURA | RA CAPITAL MANAGEMENT L.P. | 3,217,503 4.900% | 0 (Unchanged) | Filing History |
| 2025-02-03 5:39 pm Purchase | 2025-01-30 | 13D | 89bio, Inc. ETNB | RA CAPITAL MANAGEMENT L.P. | 20,013,733 15.100% | 5,759,435 (+40.40%) | Filing History |